HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Oncology

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.69.4836PMID 28129524
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• World Cancer Research Fund International

  2018cited by this paper
• CANCER TYPES;

  2018cited by this paper
• Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

  2016cited by this paper
• Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).

  2016cited by this paper
• Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual‐color in situ hybridization

  2016cited by this paper
• Droplet digital PCR measurement of HER2 in patients with gastric cancer

  2015influential reference
• Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.

  2015cited by this paper
• HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.

  2015cited by this paper
• Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.

  2015cited by this paper
• Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.

  2015cited by this paper
• Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer

  2015cited by this paper
• Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer

  2015cited by this paper
• Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with “Polysomy 17”

  2015cited by this paper
• Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.

  2015cited by this paper
• CytoLyt® Fixation and Decalcification Pretreatments Alter Antigenicity in Normal Tissues Compared With Standard Formalin Fixation

  2015cited by this paper
• Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.

  2015cited by this paper
• HER2 expression variability between primary gastric cancers and corresponding lymph node metastases.

  2015cited by this paper
• HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?

  2015cited by this paper
• Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

  2015cited by this paper
• Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.

  2015cited by this paper
• HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.

  2015cited by this paper
• Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer

  2015cited by this paper
• Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

  2015cited by this paper
• Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?

  2015cited by this paper
• Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer

  2015cited by this paper
• Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma

  2015cited by this paper
• Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction.

  2015cited by this paper
• Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China

  2015cited by this paper
• Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

  2015cited by this paper
• Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma

  2014cited by this paper
• Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer.

  2014cited by this paper
• Comprehensive molecular characterization of gastric adenocarcinoma

  2014cited by this paper
• Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer

  2014cited by this paper
• Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• Immunohistochemical HER2 expression not associated with clinicopathological characteristics of stage I-III gastric cancer patients.

  2014cited by this paper
• Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis

  2014cited by this paper
• Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer

  2014cited by this paper
• HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2 CEP17 ratio?

  2014cited by this paper
• Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization

  2014influential reference
• Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma

  2014cited by this paper
• Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis

  2014cited by this paper
• Multi-colour FISH in oesophageal adenocarcinoma—predictors of prognosis independent of stage and grade

  2014cited by this paper
• The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing

  2014cited by this paper
• High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer

  2014cited by this paper
• Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer

  2014cited by this paper
• HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

  2014influential reference
• Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program

  2014cited by this paper
• Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.

  2014cited by this paper
• Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule

  2014cited by this paper
• Quality of life in the trastuzumab for gastric cancer trial.

  2014cited by this paper
• Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.

  2014cited by this paper
• Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

  2014cited by this paper
• Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

  2014cited by this paper
• HER2 testing: current status and future directions.

  2014cited by this paper
• Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.

  2014cited by this paper
• Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.

  2014cited by this paper
• HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.

  2014cited by this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014influential reference
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2014cited by this paper
• Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

  2013cited by this paper
• HER 2 Expression in Gastric Cancer

  2013cited by this paper
• Standardized synoptic cancer pathology reports - so what and who cares? A population-based satisfaction survey of 970 pathologists, surgeons, and oncologists.

  2013cited by this paper
• Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study

  2013cited by this paper
• HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study

  2013cited by this paper
• Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.

  2013cited by this paper
• Image Cytometric HER2 in Gastric Carcinoma: Is a New Algorithm Needed?

  2013cited by this paper
• Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.

  2013cited by this paper
• Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cited by this paper
• HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.

  2013cited by this paper
• Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas

  2013cited by this paper
• Overexpression of her-2 associated with the progression of esophageal cancer patients.

  2013cited by this paper
• Flotillin2 Expression Correlates with HER2 Levels and Poor Prognosis in Gastric Cancer

  2013cited by this paper
• The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.

  2013cited by this paper
• Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population

  2013cited by this paper
• Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

  2013cited by this paper
• The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples.

  2013cited by this paper
• In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry.

  2013cited by this paper
• Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin‐fixed breast carcinoma cell block preparations: Correlation of results to corresponding tissue block (needle core and excision) samples

  2013cited by this paper
• Is Helicobacter pylori a poor prognostic factor for HER-2 SISH positive gastric cancer?

  2013cited by this paper
• Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

  2013cited by this paper
• Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

  2013cited by this paper
• HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).

  2013cited by this paper
• HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily

  2013cited by this paper
• HER2 in Gastric Cancer: An Immunohistochemical Study on Tissue Microarrays and the Coressponding Whole-Tissue Sections with a Supplemental Fish Study

  2013cited by this paper
• Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes

  2013cited by this paper
• Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.

  2013cited by this paper
• HER2-positive gastric cancer

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• HER2 expression and its clinicopathological features in resectable gastric cancer

  2013cited by this paper
• A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages

  2013cited by this paper
• Her2 Amplification in Gastric Cancer Is a Rare Event Restricted to the Intestinal Phenotype

  2013cited by this paper
• HER2 In Situ Hybridization in Gastric and Gastroesophageal Adenocarcinoma: Comparison of Automated Dual ISH to FISH

  2013cited by this paper
• Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER‐2 by immunohistochemistry in breast carcinoma

  2013cited by this paper
• HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population

  2013cited by this paper
• ER, PR, and Her2 immunocytochemistry on cell‐transferred cytologic smears of primary and metastatic breast carcinomas: A Comparison Study With Formalin‐Fixed Cell Blocks and Surgical Biopsies

  2013cited by this paper
• HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions

  2013cited by this paper
• Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)

  2012cited by this paper
• Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability

  2012cited by this paper
• Novel targeted agents for gastric cancer

  2012cited by this paper
• HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

  2012cited by this paper

• Diagnostic and Therapeutic Challenges Related to HER2 Heterogeneity in Gastric Cancer: Bridging Molecular Pathology and Clinical Decision-Making

  2026influential citation
• Methods of Engaging Interest‐Holders in Healthcare Evidence Syntheses: A Scoping Review

  2026cites this paper
• Micropapillary Urothelial Carcinoma: A Review and Update.

  2026cites this paper
• Trastuzumab Deruxtecan in Non-Breast Solid Tumors: Expanding Indications, Efficacy, and Future Directions.

  2026cites this paper
• Historical Perspective of HER2 Testing and Treatment in Prostate Cancer.

  2026cites this paper
• DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer

  2026cites this paper
• Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer.

  2026cites this paper
• HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry

  2026cites this paper
• Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?

  2026cites this paper
• Molecular Advances in Gastrointestinal Pathology.

  2026cites this paper
• Clinical effectiveness of droplet digital polymerase chain reaction technology for human epidermal growth factor receptor 2/neu gene testing in breast cancer compared to conventional methods

  2026cites this paper
• Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP).

  2026cites this paper
• Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study

  2026cites this paper
• Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

  2026cites this paper
• Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps

  2026cites this paper
• Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

  2026cites this paper
• Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy

  2026cites this paper
• The tumor microenvironment in esophageal cancer and its association with clinical features and neoadjuvant treatment response

  2026cites this paper
• Molecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis

  2026cites this paper
• Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics

  2026cites this paper
• ERBB2/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer.

  2025cites this paper
• Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us?

  2025cites this paper
• Isolated tumor cell clusters (ITC) in lymph nodes and PD-L1 expression on tumor-associated immune cells are prognostic factors for microsatellite instable-high gastric cancers

  2025cites this paper
• Human epidermal growth factor receptor 2 targeted agents in gynecologic cancers: an updated review.

  2025cites this paper
• Does paired genetic testing improve targeted therapy choices and screening recommendations for patients with upper gastrointestinal cancers and their families? A prospective cohort of 42 patients

  2025cites this paper
• Synchronous occurrence of Waldenström macroglobulinemia and HER2-positive gastric adenocarcinoma with gastrointestinal stromal tumor: a rare case report

  2025cites this paper
• Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights

  2025cites this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Urothelial Carcinoma.

  2025cites this paper
• Fidelity of Next-Generation Sequencing to Predict Human Epidermal Growth Factor 2 Overexpression Across Solid Tumors.

  2025cites this paper
• Standardization of tissue handling in veterinary pathology: How fixation affects morphological and molecular examination results

  2025cites this paper
• Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: Update and new challenges.

  2025cites this paper
• Radiological signature of HER2-Positive gallbladder cancer: analysis of CT features

  2025cites this paper
• Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas

  2025cites this paper
• Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Novel immunotherapy for gastric cancer: targeting the CD47–SIRPα axis

  2025cites this paper
• HER2 reassessment triggered by comprehensive genomic profiling reveals a therapeutic opportunity in refractory gastric cancer: a case report

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• Epithelial WNT secretion drives niche escape of developing gastric cancer

  2025cites this paper
• Primary Endometrial Gastric (Gastrointestinal)-type Mucinous Adenocarcinoma

  2025cites this paper
• Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)

  2025influential citation
• Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)

  2025cites this paper
• Jian Pi Hua Tan Fang Reverses Trastuzumab Resistance of HER2‐Positive Gastric Cancer Through PI3K/AKT/mTOR Pathway: Integrating Network Pharmacology, Molecular Docking and Experimental Validation

  2025cites this paper
• Development and clinical evaluation of [68Ga]Ga-NODAGA-ADAPT6 as a novel HER2-targeted PET radiotracer for breast cancer imaging and treatment monitoring

  2025cites this paper
• Pathologist-Artificial Intelligence (AI) Concordance in HER2 Interpretation for Advanced Biliary Tract Cancer: Intra-observer, Inter-observer, and Human-AI Variability.

  2025cites this paper
• HER2 in Gynecological Malignancies: Bridging the Gap Between Standardized Pathological Assessment and Precision Therapy.

  2025cites this paper
• HER2-low across solid tumours: different incidences and definitions.

  2025cites this paper
• Comprehensive characterization of micropapillary colorectal adenocarcinoma

  2025cites this paper
• Addressing HER2 IHC scoring discrepancies in endometrial serous carcinoma: a comparative analysis with reflex ISH.

  2025cites this paper
• Distribution and concordance of HER2 scores in endometrial and ovarian cancer.

  2025cites this paper
• Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.

  2025cites this paper
• Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings

  2025cites this paper
• Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes

  2025cites this paper
• PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study.

  2025cites this paper
• Combined anticancer effects of Chamaecytisus hirsutus extract and photodynamic therapy in Gastric cancer cells

  2025cites this paper
• Targeted DDR1 Treatment Strategy Enhances PD‑1 Immunotherapy Efficacy against Gastric Cancer

  2025cites this paper
• An evaluation of known predictive biomarkers for gastric cancer

  2025cites this paper
• MRT-HER2Net: topology-aware multi-resolution convolutional neural networks for biomarker scoring of HER2 in breast cancer

  2025cites this paper
• Multicenter prospective EN-MARK study: efficacy of third-line trastuzumab deruxtecan and dynamic changes in biomarkers, including HER2 status

  2025cites this paper
• Efficacy and Safety of Dual Therapy with HER2-inhibitors (Pertuzumab and Trastuzumab) in Gastric or Gastroesophageal Tumors: A Systematic Review and Meta-analysis

  2025cites this paper
• Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

  2025cites this paper
• Companion diagnostics and HER2-targeted antibody-drug conjugates

  2025influential citation
• A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors

  2025cites this paper
• Translational analysis of NSD3 gene amplification in lung squamous cell carcinoma: Clinical and prognostic insights from histopathological analysis of patient samples.

  2025cites this paper
• Clinicopathologic, immunohistochemical and genomic characterization of urothelial carcinoma with myxoid and chordoid features

  2025cites this paper
• HER2 and urothelial carcinoma: current understanding and future directions

  2025influential citation
• Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas.

  2025cites this paper
• HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy

  2025cites this paper
• Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization

  2025cites this paper
• Sex disparity in survival outcomes of advanced gastric adenocarcinoma

  2025cites this paper
• Spatial heterogeneity of FGFR2b in gastric cancer: a comparative analysis of primary tumors and peritoneal dissemination.

  2025cites this paper
• Artificial Intelligence for Predicting HER2 Status of Gastric Cancer Based on Whole‐Slide Histopathology Images: A Retrospective Multicenter Study

  2025cites this paper
• Automation of fluorescent in situ hybridization (FISH) leading to cost savings and consistent high-quality results

  2025cites this paper
• Evolving Precision: Updates in Targeted Therapy for Cholangiocarcinoma.

  2025cites this paper
• Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach

  2025cites this paper
• Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)

  2025cites this paper
• Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection

  2025cites this paper
• Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

  2025cites this paper
• Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression

  2025cites this paper
• Claudin 18.2 Expression in 1,404 Digestive Tract Adenocarcinomas including 1,175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes are Claudin 18.2 Positive.

  2025cites this paper
• Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital

  2025cites this paper
• Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight

  2025cites this paper
• Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy

  2025cites this paper
• Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings

  2025cites this paper
• HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions

  2025cites this paper
• Advances in the management of endometrial cancer

  2025cites this paper
• Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study

  2025cites this paper
• Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence

  2025influential citation
• Prevalence of HER2 expression and its association with clinicopathological parameters in gastric and gastroesophageal junction adenocarcinoma: A 10-year experience of an academic center

  2025cites this paper
• Classical biomarkers and non-coding RNAs associated with diagnosis and treatment in gastric cancer

  2025cites this paper
• Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

  2025cites this paper
• Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma

  2025cites this paper
• HER2 expression in cervical squamous cell carcinoma: high prevalence of HER2-low/ultralow and spatiotemporal heterogeneity across tumor evolution

  2025cites this paper
• HER2 testing: evolution and update for a companion diagnostic assay

  2025cites this paper
• Radiomics-based assessment of HER2 status and prognosis in gastric cancer: a retrospective dual-center CT study

  2025cites this paper
• Relationship between programmed cell death ligand 1 expression and the number of biopsy specimens in advanced gastric cancer

  2025cites this paper
• Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

  2025cites this paper
• Real-world outcomes of fluorouracil-based second-line therapy in patients with advanced biliary tract cancer refractory to gemcitabine and cisplatin-based treatment

  2025cites this paper
• Quantifying Tumor Budding

  2025cites this paper
• Staging of Gastric Cancer: CT Patterns and Correlation with Pathologic Findings.

  2025cites this paper
• Folate receptor alpha (FRα/FOLR1) and HER2 immunohistochemical staining in high‐grade endometrial carcinoma with aberrant p53 expression

  2025cites this paper